Recent studies have shown that treatment with B-RAF inhibitors, including both first-generation and next-generation compounds, leads to the activation of focal adhesion kinase (FAK), which in turn upregulates the Wnt/β-catenin pathway in B-RAF V600E-mutant colorectal cancer (CRC) cell lines [23]. Here, BRAF is linked to colorectal cancer.